AbbVie
ABBV
$264.96
+1.20%
AbbVie is a global pharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics, with key products including Skyrizi, Rinvoq, and Botox. As a top-tier biopharmaceutical firm, it has successfully navigated the Humira patent cliff by leveraging its next-generation immunology portfolio and strategic acquisitions like Allergan, Cerevel, and ImmunoGen. The current investor narrative centers on the company's post-Humira growth recovery, driven by Skyrizi and Rinvoq, as well as pipeline catalysts such as the Apogee Therapeutics acquisition and potential weight-loss drugs, while also addressing recent FDA manufacturing setbacks and valuation concerns after hitting new highs.…
ABBV
AbbVie
$264.96
Related headlines
Investment Opinion: Should I buy ABBV Today?
Rating: Buy. AbbVie is a high-quality pharmaceutical company with a strong growth trajectory, reasonable forward valuation, and attractive dividend. The consensus analyst rating is Buy with an average target of $275.39, implying 10.4% upside. Key supports: forward P/E of 15.3x, revenue growth of 12.4%, operating margin expansion to 31.6%, and robust free cash flow of $20.9B. Risks: FDA manufacturing issues, high payout ratio, and negative equity. This Buy would be downgraded to Hold if forward P/E exceeds 20x or revenue growth falls below 8%, and upgraded if pipeline catalysts (e.g., weight-loss drugs) succeed. Overall, the stock is fairly valued relative to its growth prospects.
Sign up to view all
ABBV 12-Month Price Forecast
AbbVie's growth trajectory is strong, supported by Skyrizi and Rinvoq, and the forward valuation is reasonable. The main risks are FDA issues and high payout ratio, but these are manageable. I would upgrade to high confidence if pipeline catalysts materialize, and downgrade to neutral if revenue growth slows below 8% or FDA issues escalate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $276.59 and implied upside of +4.4% versus the current price.
Average Target
$276.59
0 analysts
Implied Upside
+4.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$200 - $328
Analyst target range
With 28 analysts covering AbbVie, the consensus recommendation is a 'Buy' (mean rating of 1.74), and the average price target is $275.39, implying a 10.4% upside from the current price of $249.46. The target range is $200 to $328, with the high target suggesting strong confidence in pipeline catalysts and growth, while the low target reflects concerns about competition and regulatory risks. Recent ratings from major firms like UBS, BMO, and Wells Fargo have been positive, with no downgrades, indicating a bullish sentiment among analysts.
Bulls vs Bears: ABBV Investment Factors
AbbVie presents a compelling post-Humira growth story, with Skyrizi and Rinvoq driving double-digit revenue growth and a reasonable forward valuation. The bull case is supported by strong operational metrics, robust free cash flow, and a consensus Buy rating. However, the bear case highlights elevated trailing earnings, negative equity, and premium valuation relative to peers. The most critical tension is whether the company can sustain its growth trajectory and improve earnings to justify the current valuation, especially given the high payout ratio and recent FDA setback. Currently, the bull case has stronger evidence, as the forward P/E is reasonable and growth is accelerating, but investors should monitor earnings recovery and pipeline execution.
Bullish
- Skyrizi and Rinvoq drive 12.4% revenue growth: Q1 2026 revenue reached $15.0B, up 12.4% YoY, driven by Skyrizi ($4.48B) and Rinvoq ($2.12B), which are more than offsetting Humira's decline ($0.69B). This demonstrates successful portfolio transition post-Humira patent cliff.
- Forward P/E of 15.3x is attractive: Despite a trailing P/E of 96.4x due to acquisition charges, the forward P/E of 15.3x is near the lower end of its 3-year range (15x-84x), implying the market expects significant earnings growth. This suggests the stock is not overvalued relative to its own history.
- Strong operating margin expansion: Operating margin improved to 31.6% in Q1 2026 from 28.0% a year ago, indicating strong operational leverage. Gross margin remains high at 70.2%, supported by a high-margin product mix.
- Robust free cash flow of $20.9B TTM: Trailing twelve-month free cash flow of $20.9B provides ample coverage for dividends and debt, supporting the company's Dividend King status and financial flexibility for acquisitions like Apogee ($10.9B).
Bearish
- Elevated trailing P/E of 96.4x: The trailing P/E is extremely high due to acquisition-related charges depressing net income. While forward P/E is lower, the current earnings power is weak, and any earnings miss could lead to multiple compression.
- Negative equity from aggressive buybacks: Debt-to-equity ratio is -21.1 due to negative shareholders' equity, a result of heavy share repurchases. This financial structure increases risk, especially if cash flows decline or interest rates rise.
- FDA manufacturing setback for TrenibotE: AbbVie received an FDA rejection for TrenibotE due to manufacturing issues, a near-term delay that could impact aesthetics revenue and investor sentiment, though the drug's science is sound.
- Premium valuation vs. industry: P/S ratio of 6.65x is above the industry average of 4.5x, indicating a premium. If growth decelerates, the stock could de-rate, especially given its recent run to near 52-week highs.
ABBV Technical Analysis
AbbVie's stock is in a strong uptrend, with a 1-year price change of +21.88%, and is currently trading at $249.46, which is 93.3% of its 52-week range (low: $190.75, high: $267.47). This positioning near the highs indicates robust momentum, though it also suggests the stock may be overextended in the short term, as it sits just 6.7% below its 52-week high. The stock's beta of 0.28 indicates significantly lower volatility than the broader market, making it a defensive holding, but its relative strength over the past year (1.51 vs. SPY) shows it has outperformed the market, reflecting strong investor confidence.
Beta
0.28
0.28x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$191-$267
Price range past year
Annual Return
+26.5%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | +4.6% | +2.5% |
| 3m | +22.8% | +2.7% |
| 6m | +17.9% | +11.1% |
| 1y | +26.5% | +20.5% |
| ytd | +15.5% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
AbbVie's revenue growth is accelerating, with Q1 2026 revenue of $15.0 billion, up 12.4% year-over-year, and a sequential increase from $13.3 billion in Q1 2025. The growth is driven by Skyrizi ($4.48 billion) and Rinvoq ($2.12 billion), which are offsetting Humira's decline ($0.69 billion). The company's gross margin remains high at 70.2%, and operating margin improved to 31.6% in Q1 2026, up from 28.0% in the year-ago quarter, indicating strong operational leverage. Net income of $699 million in Q1 2026 was impacted by acquisition-related charges, but the trailing twelve-month free cash flow of $20.9 billion provides ample coverage for dividends and debt, with a current ratio of 0.67 and a debt-to-equity ratio of -21.1 (due to negative equity from buybacks), which is a concern but manageable given strong cash generation.
Quarterly Revenue
$15.0B
2026-03
Revenue YoY Growth
+12.4%
YoY Comparison
Gross Margin
71.9%
Latest Quarter
Free Cash Flow
$20.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Given positive net income, the trailing P/E of 96.4x is elevated, but the forward P/E of 15.3x is much more reasonable, implying the market expects significant earnings growth. The P/S ratio of 6.65x is above the industry average of 4.5x, indicating a premium valuation, but this is justified by AbbVie's superior growth and profitability. Historically, the stock's P/E has ranged from 15x to 84x over the past three years, and the current forward P/E is near the lower end, suggesting the stock is not overvalued relative to its own history, despite the recent price surge.
PE
96.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~139x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high trailing P/E of 96.4x, which could compress if earnings disappoint, and a negative equity position (debt-to-equity -21.1) from aggressive buybacks, increasing financial leverage. The dividend payout ratio of 275.8% of earnings is concerning, though free cash flow of $20.9B covers it. Revenue concentration in immunology (Skyrizi and Rinvoq) is a risk if competition emerges, but current growth is strong. Acquisition-related charges have depressed net income, but operating margin expansion to 31.6% shows underlying profitability.
FAQ
Key risks include: 1) Financial: high payout ratio (275.8%) and negative equity from buybacks, though free cash flow covers dividends. 2) Regulatory: FDA manufacturing issues for TrenibotE could delay revenue. 3) Competitive: potential biosimilar competition for Skyrizi and Rinvoq. 4) Macro: low beta (0.28) reduces market risk, but interest rate hikes could compress valuations. The most severe risk is a pipeline failure, which could lead to a -20% drop to the 52-week low of $190.75.
The 12-month forecast is positive, with a base case target of $260-280 (50% probability), bull case of $280-328 (30%), and bear case of $200-230 (20%). The most likely scenario is the base case, driven by continued growth of Skyrizi and Rinvoq. Analysts' average target is $275.39, implying 10.4% upside. Key assumption is that revenue growth remains above 10%.
ABBV's forward P/E of 15.3x is near the lower end of its 3-year range (15x-84x), suggesting it is not overvalued relative to its own history. However, its P/S ratio of 6.65x is above the industry average of 4.5x, indicating a premium. The market is pricing in strong earnings growth, which is supported by the 12.4% revenue growth. Overall, it is fairly valued given its growth prospects.
ABBV is a good buy for investors seeking a defensive growth stock with a solid dividend. The consensus analyst target of $275.39 implies 10.4% upside, and the forward P/E of 15.3x is reasonable. However, the trailing P/E is high at 96.4x, and the payout ratio is elevated. It's a good buy for those with a long-term horizon who can tolerate short-term volatility, but not for those seeking quick gains.
ABBV is better suited for long-term investment due to its defensive nature (beta 0.28), strong dividend, and growth trajectory. Short-term trading is possible given its volatility, but the stock's value lies in its long-term pipeline and dividend growth. A minimum holding period of 3-5 years is recommended to fully benefit from the growth of Skyrizi and Rinvoq and pipeline catalysts.